Human tissue kallikreins 3 and 5 can act as plasminogen activator releasing active plasmin.

[1]  A. Scorilas,et al.  Kallikrein-related peptidases in prostate, breast, and ovarian cancers: from pathobiology to clinical relevance , 2012, Biological chemistry.

[2]  M. Blaber,et al.  Biological evaluation and docking studies of natural isocoumarins as inhibitors for human kallikrein 5 and 7. , 2011, Bioorganic & medicinal chemistry letters.

[3]  M. Blaber,et al.  Substrate specificity and inhibition of human kallikrein-related peptidase 3 (KLK3 or PSA) activated with sodium citrate and glycosaminoglycans. , 2010, Archives of biochemistry and biophysics.

[4]  E. Diamandis,et al.  Utility of kallikrein-related peptidases (KLKs) as cancer biomarkers. , 2008, Clinical chemistry.

[5]  Yongping Cui,et al.  ECRG2 inhibits cancer cell migration, invasion and metastasis through the down-regulation of uPA/plasmin activity. , 2007, Carcinogenesis.

[6]  G. Sotiropoulou,et al.  Tissue kallikrein proteolytic cascade pathways in normal physiology and cancer. , 2007, Biochimica et biophysica acta.

[7]  L. Luo,et al.  Inhibition profiles of human tissue kallikreins by serine protease inhibitors , 2006, Biological chemistry.

[8]  X. Tan,et al.  Analysis of the invasion-metastasis mechanism in pancreatic cancer: involvement of plasmin(ogen) cascade proteins in the invasion of pancreatic cancer cells. , 2006, International journal of oncology.

[9]  P. Opolon,et al.  Full kringles of plasminogen (aa 1–566) mediate complete regression of human MDA-MB-231 breast tumor xenografted in nude mice , 2005, Gene Therapy.

[10]  E. Diamandis,et al.  Biochemical and Enzymatic Characterization of Human Kallikrein 5 (hK5), a Novel Serine Protease Potentially Involved in Cancer Progression* , 2005, Journal of Biological Chemistry.

[11]  E. Diamandis,et al.  The emerging roles of human tissue kallikreins in cancer , 2004, Nature Reviews Cancer.

[12]  G. Yousef,et al.  The new human tissue kallikrein gene family: structure, function, and association to disease. , 2001, Endocrine reviews.

[13]  R. Kontermann,et al.  Generation of angiostatin-like fragments from plasminogen by prostate-specific antigen , 1999, British Journal of Cancer.

[14]  C. Lazure,et al.  Prostatic kallikrein hK2, but not prostate‐specific antigen (hK3), activates single‐chain urokinase‐type plasminogen activator , 1997, International journal of cancer.

[15]  A. Ito,et al.  Internally quenched fluorogenic protease substrates: Solid-phase synthesis and fluorescence spectroscopy of peptides containing ortho-aminobenzoyl/dinitrophenyl groups as donor-acceptor pairs , 1995, Letters in Peptide Science.

[16]  H. Kobayashi,et al.  Inhibition of the soluble and the tumor cell receptor-bound plasmin by urinary trypsin inhibitor and subsequent effects on tumor cell invasion and metastasis. , 1994, Cancer research.

[17]  E. Davie,et al.  Characterization of the gene for human plasminogen, a key proenzyme in the fibrinolytic system. , 1990, The Journal of biological chemistry.

[18]  S. Strickland,et al.  Interaction of heparin with plasminogen activators and plasminogen: effects on the activation of plasminogen. , 1986, Biochemistry.

[19]  Lijuan Zhang.  Glycosaminoglycan (GAG) biosynthesis and GAG-binding proteins. , 2010, Progress in molecular biology and translational science.

[20]  E. Davie,et al.  23 The isolation and characterization of the gene for human plasminogen , 1988 .